Traitement des cancers bronchopulmonaires non à petites cellules métastatiques: Quelle chimiothérapie?

The therapeutic strategy of metastatic non-small-cell lung cancer (NSCLC) has known a qualitative evolution these last ten years. The added value of chemotherapy versus palliative care has been demonstrated by several meta-analyses. New molecules with better efficacy-toxicity ratio (vinorelbine, paclitaxel, docetaxel, gemcitabine, pemetrexed) improved the therapeutic strategy according to the patient performance status. Platinum-based combination remains the standard of care in first line treatment with a median survival of 8 months and a one-year median survival of 35%, while no particular doublet shown its superiority. Currently, a second line treatment is a standard. Regarding targeted therapies, their role in NSCLC are under way.